Trials / Not Yet Recruiting
Not Yet RecruitingNCT06134960
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | KD-496 | Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells |
Timeline
- Start date
- 2023-11-16
- Primary completion
- 2026-06-30
- Completion
- 2026-11-15
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06134960. Inclusion in this directory is not an endorsement.